贵州三力（603439）7月30日主力资金净流出1989.16万元

Core Insights - Guizhou Sanli Pharmaceutical Co., Ltd. reported a decline in both revenue and net profit for the first quarter of 2025, with total revenue at 409 million yuan, down 3.18% year-on-year, and net profit at 41.95 million yuan, down 25.16% [1] Financial Performance - Total revenue for Q1 2025: 409 million yuan, a decrease of 3.18% year-on-year [1] - Net profit attributable to shareholders: 41.95 million yuan, a decrease of 25.16% year-on-year [1] - Non-recurring net profit: 38.58 million yuan, a decrease of 31.56% year-on-year [1] - Current ratio: 1.511 [1] - Quick ratio: 1.207 [1] - Debt-to-asset ratio: 47.82% [1] Stock Performance - As of July 30, 2025, the stock price closed at 13.29 yuan, down 0.97% [1] - Turnover rate: 5.48% [1] - Trading volume: 221,500 lots [1] - Trading amount: 297 million yuan [1] - Net outflow of main funds: 19.89 million yuan, accounting for 6.7% of trading volume [1] Investment and Intellectual Property - Guizhou Sanli has invested in 14 companies and participated in 2,352 bidding projects [2] - The company holds 120 trademark registrations and 69 patents [2] - The company has 70 administrative licenses [2]